MEDS — DataMeds AI, Inc.

—
Nasdaq · Consumer Discretionary · Distributors · CIK 2030763 ·
Last close
$0.64
Market Cap
$3.32M
52W High
$33.15
52W Low
$0.49
ADV30
1,911,359
Next earnings
—
DataMEDS AI, Inc. operates as a health IT company in the United States. The company focuses on the vertical integration of technology, pharmacy, pharmaceutical-adjacent, and telemedicine business units to deliver an enhanced healthcare experience for consumers. It offers tools, such as the EinsteinRx, a pharmacy dispensing AI platform; the PharmacyChain, a smart contracts platform; Patient Rx Adherence Tool; and HubRx AI. It also operates as a pharmacy distributor; and provides clinical concierge services. DataMEDS AI, Inc., through its subsidiary develops and delivers a portfolio of products to guide physicians and patients with difficult clinical decisions throughout the cancer care continuum. In addition, the company develops and provides functional precision medicine oncology platform. The company was formerly known as Wellgistics Health, Inc. and changed its name to DataMEDS AI, Inc. in July 2026. DataMEDS AI, Inc. was incorporated in 2022 and is based in Tampa, Florida.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 2,668,980 431,880 -3,373,956 10,589,764 38,733,868 476,598 38,562,173
Jun 2026 1,779,860 182,204 -7,345,054 -18,363,225 32,759,432 2,456,373 52,263,663
Mar 2026 1,559,563 170,221 -6,015,538 -7,742,597 30,127,690 51,730 45,190,139
Dec 2025 1,670,648 -7,855,824 -12,797,758 -27,852,959 30,459,449 42,571 42,907,250

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-13,735,909
Investing CF
$-923,697
Financing CF
$16,696,038
CapEx
$-923,697
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-39.03
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-137,137,512
Inventory
$1,510,123
Receivables
$1,200,404
ST Investments
—
EBIT TTM
$-82,342,040
Pretax Income TTM
$-88,276,985
Interest Exp TTM
$5,934,945
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$8,022,975
EBITDA
$-55,387,860
Free Cash Flow
$2,370,213
Enterprise Value
$32,443,636
Total Cash
$2,456,373
Total Debt
$32,622,248
Shares Out
5,182,529
Trailing EPS
$-46.68
Book Value
$-6.14
ROE
—
ROA
-82.9%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 23,337,860 -81,194,831 -101,274,530 30,459,449 42,907,250 -12,447,801 -10,855,029
Dec 2024 18,128,831 -6,145,132 -6,856,226 57,332,650 50,598,204 6,734,446 -1,224,993
Dec 2023 0 -2,880,603 -2,895,684 338,364 3,238,798 -2,900,434 -349,136
Dec 2022 32,777,728 -3,422,729 -2,743,800 0 5,250 -5,250 0

TTM Snapshot

Revenues TTM
$8,022,975
NetIncome TTM
$-88,276,985
OpCashFlow TTM
—
Assets (Latest)
$32,759,432
Forward EPS
—

Peers — same industry

TickerNameMarket CapLastDaily %
HYFM HYDROFARM HOLDINGS GROUP, INC. $3.28M $0.68 —
BANL CBL International Ltd $3.44M $3.13 —
BGMS Bio Green Med Solution, Inc. $3.91M $0.59 —
CGTL Creative Global Technology Holdings Ltd $2.81M $2.44 —
GDC GD Culture Group Ltd $4.37M $1.05 —

News headlines (Yahoo Finance, 1h cache)

DataMeds AI Signs Preliminary Agreement With Florida Health Insurer for GLP-1 Patient Management App
2026-11-05 11:49 · Yahoo
DataMEDS AI Secures Supply Agreement for Six Compounded Peptides Following FDA Advisory Committee Recommendations
2026-11-02 11:42 · Yahoo
DataMEDS AI Establishes "Health Lives Here" Community Respiratory Program for Corexa Health Pharmacy Network
2026-10-23 10:45 · Yahoo
DataMeds Regains Compliance With NASDAQ Listing Standards
2026-10-20 10:00 · Yahoo
DataMeds AI Plans Peptide Compounding Expansion Through Corexa Health Following FDA Policy Proposal
2026-10-16 10:56 · Yahoo
DataMeds Applauds FDA's Proposed Interim Access Policy for Compounding Using Certain Peptides and Provides Corexa Health's Peptides Roadmap
2026-10-16 10:00 · Yahoo
DataMEDS Si Licenses U.S. Rights To Reboot Health AI's Direct-To-Consumer GLP-1 Weight Management Platform
2026-10-14 13:48 · Yahoo
DataMEDS SI Provides Business Update On CLIA Lab Helomics And Its Super Intelligence Predictive Oncology Division
2026-10-13 16:11 · Yahoo
DataMeds AI Announces Workforce Reductions as It Prioritises ChemoFx Cancer Diagnostic Test Commercialisation
2026-10-13 11:02 · Yahoo
DataMeds AI Secures Medicaid Coverage for ChemoFx Assay in Gynecologic Cancers
2026-10-12 14:48 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.